17-1969-41
antibody from Invitrogen Antibodies
Targeting: CCR6
BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-1969-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD196 (CCR6) Monoclonal Antibody (R6H1), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This R6H1 monoclonal antibody reacts with CD196 (also known as CCR6), a seven transmembrane G protein-coupled receptor expressed on T, B, dendritic, natural killer, and Langerhans cells. This CC chemokine receptor uniquely binds MIP-3a/CCL20, a chemoattractant for dendritic cells, effector/memory T cells, and B cells. CD196 is also involved in host defense and inflammation at epithelial sites. Furthermore, this receptor has been implicated in Th17 differentiation and CD4+FoxP3+ regulatory T cell development. Applications Reported: This R6H1 antibody has been reported for use in flow cytometric analysis. Applications Tested: This R6H1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- R6H1
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references CCL20 Secretion from the Nucleus Pulposus Improves the Recruitment of CCR6-Expressing Th17 Cells to Degenerated IVD Tissues.
BET bromodomain inhibition suppresses TH17-mediated pathology.
Down-regulation of the beta-chemokine receptor CCR6 in dendritic cells mediated by TNF-alpha and IL-4.
Zhang W, Nie L, Wang Y, Wang XP, Zhao H, Dongol S, Maharjan S, Cheng L
PloS one 2013;8(6):e66286
PloS one 2013;8(6):e66286
BET bromodomain inhibition suppresses TH17-mediated pathology.
Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM
The Journal of experimental medicine 2013 Oct 21;210(11):2181-90
The Journal of experimental medicine 2013 Oct 21;210(11):2181-90
Down-regulation of the beta-chemokine receptor CCR6 in dendritic cells mediated by TNF-alpha and IL-4.
Carramolino L, Kremer L, Goya I, Varona R, Buesa JM, Gutiérrez J, Zaballos A, Martínez-A C, Márquez G
Journal of leukocyte biology 1999 Nov;66(5):837-44
Journal of leukocyte biology 1999 Nov;66(5):837-44
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD19 eFluor® 450 (Product # 48-0199-42) and Mouse IgG1 K Isotype Control APC (Product # 17-4714-81) (left) or Anti-Human CD196 (CCR6) APC (right). Cells in the lymphocyte gate were used for analysis.